Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-07-29
2000-04-11
Shah, Mukund J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
544277, A01N 4390
Patent
active
060488654
ABSTRACT:
A series of adenosine-5'-uronamide derivatives bearing N.sup.6 -arylurea, alkarylurea, heteroarylurea, arylcarbonyl, alkarylcarbonyl or heteroarylcarbonyl groups which have affinity and, in some cases, selectivity for the adenosine A.sub.1 or A.sub.3 receptors are disclosed. These compounds can be used in a pharmaceutical composition to treat disorders caused by excessive activation of the A.sub.1 or A.sub.3 receptors, or can be used in a diagnostic application to determine the relative binding of other compounds to the A.sub.1 or A.sub.3 receptors.
REFERENCES:
patent: 5310731 (1994-05-01), Olsson et al.
Abbracchio, M.P. et al., G Protein-Dependent Activation of Phospholipase C by Adenosine A.sub.3 Receptors in Rat Brain, Mol. Pharmacol, vol. 48, No. 6, pp. 1038-1045 (1995).
Baraldi et al., Synthesis of new pyrazolo [4,3-e]-1,2,4-triazolo[1,5-c] pyrimidine and 1,2,3-triazolo[4,5-e] 1,2,4-triazolo [1,5-c]pyrimidine displaying potent and selective activity as A.sub.2a adenosine receptor antagonist, Bioorg. Med. Chem. Lett. vol. 4, pp. 2539-2544 (1994).
Baraldi et al., Current Developments of A.sub.2a Adenosine Receptor Antagonists, Current Medicinal Chemistry, vol. 2, pp. 707-722 (1995).
Gallo-Rodriguez, et al., Structure-Activity Relationship of N.sup.6 -Benzyladenosine-5'-uronamides as A.sub.3 -Selective Adenosine Agonists, J. Med. Chem. vol. 37, pp. 636-646 (1994).
Jacobson, "Adenosine A.sub.3 receptors: novel ligands and paradoxical effects," TIPS, vol. 19, pp. 185-191, (May 1998).
Jacobson, et al., Adenosine Receptors: Pharmacology, Structure-Activity Relationships, and Therapeutic Potential, J. Med. Chem. vol. 35, No. 3, pp. 407-422 (1992).
Jacobson, et al., Structure-Activity Relationships of 8-Styrylxanthines as A.sub.2 -Selective Adenosine Antagonists, J. Med. Chem, vol. 36, pp. 1333-1342 (1993).
Jacobson, et al., A role for central A.sub.3 -adenosine receptors: Mediation of behavioral depressant effects, FEBS Lett, vol. 336, pp. 57-60 (1993).
Jacobson, et al., A.sub.3 -adenosine receptors: design of selective ligands and therapeutic prospects, Drugs of the Future, vol. 20(7), pp. 689-699 (1995).
Jacobson, et al. Structure-Activity Relationships of 9-Alkyladenine and Ribose-Modified Adenosine Derivatives at Rat A.sub.3 Adenosine Receptors, J. Med. Chem., vol. 38, pp. 1720-1735 (1995).
Jiang J. et al., 6-Phenyl-1,4-dihydropyridine Derivatives as Potent and Selective A.sub.3 Adenosine Receptor Antagonists, J. Med. Chem., vol. 39, pp. 4667-4675 (1996).
Jiang J. et al., Structure-Activity Relationships of 4-(phenylethylnyl)-6-phenyl-1,4-dihydropyridines as Highly Selective A.sub.3 Adenosine Receptor Antagonists, J. Med. Chem., vol. 40, pp. 2596-2608 (1997).
Karton, Y. et al., Synthesis and Biological Activities of Flavnoid Derivatives as A.sub.3 Adenosine Receptor Antagonists, J. Med. Chem., vol. 39 pp. 2293-2301 (1996).
Kim, H.O. et al., 2-Substitution of N.sup.6 -Benzyladenosine-5'-uronamides Enhances Selectivity for A.sub.3 Adenosine Receptors, J. Med. Chem. vol. 37, pp. 3614-3621 (1994).
Kim, Y.C. et al., Derivatives of the Triazoloquinazoline Adenosine Antagonist Are Selective for the Human A.sup.3 Receptor Subtype, J. Med. Chem., vol. 39 pp. 4142-4148 (1996).
Kohno et al., Induction of Apoptosis in HL-60 Human Promyelocytic Leukemia Cells by Adenosine A.sub.3 Receptor Agonists, Biochm. Biophy. Res. Comm. V. 219, pp. 904-910 (1996).
Linden, J., Cloned adenosine A.sub.3 receptors-pharmacological properties, species, differences and receptor functions, Trends Pharmacol, Sci., vol. 15, pp. 298-300 (1994).
Mathot et al., Deoxyribose analogues of N.sup.6 -cyclopentyladenosine (CPA): partial agonists at the adenosine A.sub.1 receptor in vivo, Brit J. Pharmacol, vol. 116, pp. 1957-1964 (1995).
Olah, M.E. et al., [.sup.125 l1-4-Aminobenzyl5'-N-methylcarboxamidoadenosine, a High Affinity Radioligand for the Rat A.sub.3 Adenosine Receptor, Mol. Pharm., vol. 45, pp. 978-982 (1994).
Siddiqi, S.M., et al., Comparative Molecular Field Analysis of Selective A.sub.3 Adenosine Receptor Agonists, Bioorg. Med. Chem., vol. 3, pp. 1331-1343 (1995).
van Bergen A., et al., A.sub.3 Receptors: Structure Activity Relationships and Molecular Modeling, ACS 206th National Meeting, Abstract MED217 (1993).
van Calenbergh, N.sup.6 -Cyclopentyl-3'-substituted-xylofuranosyladenosines: A New Class of Non-Xanthine Adenosine A.sub.1 Receptor Antagonists, J. Med. Chm, V40, p3765-3772 (1997).
van Galen, P.J.M., et al., A Binding Site Model and Structure-Activity Relationships for the Rat A.sub.3 Adenosine Receptor, Mol. Pharmacol, vol. 45, pp. 1101-1111 (1994).
van Rhee, et al., Interaction of 1,4-Dihydropyridine and Pyridine Derivatives with Adenosine Receptors: Selectively for A.sub.3 Receptors, J. Med. Chem., vol. 39, pp. 2980-2989 (1996).
van Rhee, A.M. et a., Tetrahydrobenzothiophenone Derivatives as a Novel Class of Adenosine, J. Med. Chem., vol. 39, pp. 398-406 (1996).
von Lubitz, D.K.J.E., et al., Adenosine A.sub.3 receptor stimulation and cerebal ischemia, Eur. J. Pharmacol, vol. 263, pp. 59-67 (1994).
Zhou, Q.Y. et al., Molecular cloning and characterization of an adenosine receptor:The A.sub.3 adenosine receptor, Proc. Natl. Acad. Sci. USA, vol. 89, pp. 7432-7436 (1992).
Baraldi et al., "Novel N6-(Substituted-phenylcarbamoyl)adenosine-5;-uronamides as Potent Agonists for A3 Adenosine Receptors," J. Med. Chem., vol. 39, No. 3, pp. 802-806, Feb. 2, 1996.
Von Lubitz et al., "Adenosine A3 receptor stimulation and cerebral ischemia," Eur. J. Pharmacol., vol. 263, No. 1-2, pp. 59-67, MEDLINE abstract, Sep. 1994.
Stambaugh et al., "A novel cardioprotective function of adenosine A1 and A3 receptors during prolonged simulated ischemia," Am. J. Physiol., vol. 273, No. 1 Pt. 2, pp. 501-505, MEDLINE abstract, Jul. 1997.
Reeves et al., "Adenosine A3 receptors promote degranulation of rat mast cells both in vitro and in vivo," Inflamm. Res., vol. 46, No. 5, pp. 180-184, MEDLINE abstract, May 1997.
Keller, "Arteriolar constriction in skeletal muscle during vascular stunning: Role of Mast Cells," Am. J. Physiol., vol. 272, No. 5 Pt. 2), pp. 2154-2163, MEDLINE abstract, May 1997.
Monti et al., "p-SPA, a peripheral adenosine A1 analogue, reduces sleep apneas in rats," Pharmacol. Biochem. Behav., vol. 53, No. 2, pp. 341-345, MEDLINE abstract, Feb. 1996.
Kessinger Ann M.
Medco Research, Inc.
Shah Mukund J.
LandOfFree
N.sup.6 -substituted-adenosine-5'-uronamides as adenosine recept does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with N.sup.6 -substituted-adenosine-5'-uronamides as adenosine recept, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and N.sup.6 -substituted-adenosine-5'-uronamides as adenosine recept will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1176862